Otros idiomas PAVmed Inc.

Acciones

PAVM

US70387R4039

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 16/07/2024			Varia. Cinco días.	Varia. 1 de enero.
1,04 ^USD	+10,64 %		+33,33 %	-74,76 %

02/07	Lucid Diagnostics anuncia datos positivos de su estudio prospectivo, internacional y multicéntrico ESOGUARD BE-1 de validación clínica de la prueba de precáncer esofágico Esoguard en una población de cribado	CI
20/06	Transcript : PAVmed Inc. - Shareholder/Analyst Call

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Lucid Diagnostics Launches New Corporate Website	11/07
Lucid Diagnostics Announces Positive Data from Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population	02/07
4,000th Firefighter Undergoes Lucid Diagnostics EsoGuard Esophageal Precancer Testing	13/06
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	13/06
PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall	09/05
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors	07/05
Pavmed Inc. Appoints Dennis Matheis to Board of Directors	07/05
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024	06/05
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024	03/05
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024	02/05
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	30/04
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month	29/04
PAVmed : Material Agreement - Form 8-K	26/04
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	08/04
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	21/03
PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX	21/03
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference	20/03
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024	13/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas PAVmed Inc.

Acciones

PAVM

US70387R4039

Otros idiomas

Filtros